Visit the ACCC COVID-19 Resource Center & Listserv for Insights on Providing Optimal Patient Care During the Pandemic.
 
Home / Learn / Immunotherapy / View All IO Resources

View All IO Resources

Here is a comprehensive list of all of our immuno-oncology resources. Enter your search terms in the box below to filter your results.

Displaying results 1 - 20 of 53

1 2 3 Next
March 3, 2021
Washington Hilton 1919 Connecticutt Ave. NW Washington, D.C. 20009 202-483-3000
Discover the results of the 2019 Trending Now in Cancer Care Survey—what tops the list of challenges, what areas are trending towards growth, and how cancer programs are evolving to meet the demands of 21st-century cancer care delivery.
How do interest specialists outside the field of oncology in participating in an inter-specialty immune-related adverse events (irAEs) tumor board? Cleveland Clinic discovered the key is to recruit physician champions who are not oncologists.
Johns Hopkins was one of the first institutions to use immunotherapies to treat intractable cancers. Because IO therapies can affect any of the body's organ systems, there was early recognition of the value of having a multidisciplinary team of organ specialists who could bring their expertise to the treatment of patients experiencing immune-related adverse events (irAEs).
We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.
ACCC’s Immuno-Oncology Institute has developed the Survivorship Care Plans for Patients Receiving Immunotherapy as a resource for cancer programs and practices. and describes processes for developing survivorship care plans (SCPs) for patients treated with immunotherapy, effective practices in SCP design, and considerations for SCP delivery for this patient population.
December 9, 2019
With an increasing demand for cancer care services in a growing population, telemedicine and technology are becoming a vital component of delivering high-quality, value-based cancer care. Innovative e-health platforms and virtual navigation services can improve patient care by mitigating barriers for patients who are appropriate for cancer immunotherapy treatment, yet implementation of, and reimbursement …
Learn why a trip to the emergency department is different for patients who receive immunotherapy for cancer, what information helps ED clinicians, and what busy emergency department providers need to know about immune-related adverse events.
Many organizations have published formal recommendations, or workup guidelines, for managing irAEs, including ASCO, ESMO, NCCN, and SITC.The following can be used as a directory for the current irAE workup guidelines.
Download a summary of what occured during the ACCC 45th Annual Meeting & Cancer Center Business Summit in March 2019, where a Deep Dive Workshop on Real-World Integration of Immuno-Oncology brought together an expert panel for a focused discussion on step therapy in the context of immunotherapeutics. Panelists explored step therapy from the perspective of different members of the care team, including …
Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.
Access to new cancer immunotherapies is important for patients in an increasing number of cancers. Integrating costly paradigm-changing treatments into practice requires expertise from the oncology pharmacist working closely with administration, oncology nursing, and new team members such as oncology financial navigators.
Through its immunotherapy initiative, ACCC has developed a medical wallet card for patients on immunotherapy for cancer. A downloadable print-ready PDF enables cancer programs & practices to have copies printed.
Our busy community practice first began treating patients with immunotherapy through participating in the original ipilimumab clinical trials. We quickly realized that this new treatment paradigm would require us to create and implement an effective screening and management tool for our immunooncology (IO) patient population.
Immuno-oncology (IO) has radically altered the patient care paradigm. One of most important changes attributed to IO is improvement in outcomes and lengthening of survival. This good news comes with multiple challenges, not least of which is the need for new and better communication and coordination among multiple specialties over time.
Immune-related adverse events (irAEs) are extremely common in patients being treated with checkpoint inhibitors for advanced melanoma. The type, quality, and severity of these adverse events, however, varies by treatment regimen and by patient.
Are you leveraging the assets of your oncology pharmacists in delivery of immunotherapy for cancer? Oncology pharmacists multidisciplinary team members who help bridge the gap between science and real-world medical practice. Sarah Hudson-DiSalle, PharmD, RPh, describes how your IO program can make the best use of the oncology pharmacist's diverse skillset.
Presented at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco, CA.
Presented at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco, CA.
Presented at the 2019 Alliance Annual Conference in National Harbor, MD.

Displaying results 1 - 20 of 53

1 2 3 Next